SLC39A1: A Protein Involved in Neurotransmission and Multiple Cellular Processes

Target Name: SLC39A1

NCBI ID: G27173

SLC39A1

SLC39A1: A Protein Involved in Neurotransmission and Multiple Cellular Processes

SLC39A1, also known as Transient receptor potential cation channel subfamily 39 member 1, is a protein that plays a crucial role in many cellular processes in the brain. It is a cation channel that is involved in the regulation of neurotransmitter release and is expressed in high levels in the brain.

SLC39A1 is a member of the Transient receptor potential (TRP) gene family, which is known for its role in the regulation of sensory perception and neurotransmission. The TRP gene family has four subfamilies, including SLC39A1, which is involved in the regulation of neurotransmitter release.

SLC39A1 is a 120-kDa protein that is expressed in the brain and other tissues. It is localized to the end of the axon of neurons and is involved in the regulation of neurotransmitter release. SLC39A1 is primarily expressed in the prefrontal cortex, which is responsible for many higher-order cognitive functions, such as decision-making, problem-solving, and planning.

SLC39A1 is involved in the regulation of several neurotransmitter systems, including the regulation of dopamine (DA) release. Dopamine is a neurotransmitter that is involved in motor control, regulation mood, and many other cellular processes. SLC39A1 is known to play a role in the regulation of DA release by allowing neurotransmitters to bind to its extracellular domain and increasing the likelihood of neurotransmitter release.

SLC39A1 is also involved in the regulation of neurotransmitter release in response to changes in the levels of neurotransmitters in the brain. For example, SLC39A1 is known to play a role in the regulation of neurotransmitter release in response to changes in the levels of GABA, a neurotransmitter that is involved in the regulation of anxiety and other mood-related behaviors.

In addition to its role in neurotransmission, SLC39A1 is also involved in the regulation of several other cellular processes. For example, it is known to play a role in the regulation of ion channels in the brain and is involved in the regulation of the flow of ions into and out of neuronal cells. SLC39A1 is also involved in the regulation of the stability of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain.

SLC39A1 is a potential drug target for several diseases, including Alzheimer's disease, Parkinson's disease, and anxiety disorders. Given its involvement in the regulation of neurotransmission and its role in the regulation of multiple cellular processes, SLC39A1 may be a valuable target for the development of new treatments for these diseases.

In conclusion, SLC39A1 is a protein that plays a crucial role in many cellular processes in the brain. It is a cation channel that is involved in the regulation of neurotransmission and is expressed in high levels in the brain. SLC39A1 may be a drug target for several diseases, including Alzheimer's disease, Parkinson's disease, and anxiety disorders due to its involvement in the regulation of neurotransmission and its role in the regulation of multiple cellular processes. Further research is needed to fully understand the role of SLC39A1 in neural function and the potential of SLC39A1 as a drug target.

Protein Name: Solute Carrier Family 39 Member 1

Functions: Transporter for the divalent cation Zn(2+). Mediates the influx of Zn(2+) into cells from extracellular space (PubMed:11301334, PubMed:12888280, PubMed:16844077). Functions as the major importer of zinc from circulating blood plasma into prostate cells (PubMed:12888280)

The "SLC39A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC39A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets